• news.cision.com/
  • Follicum/
  • Follicum AB receives Notice of Allowance from the U.S. Patent Office for method of stimulating hair growth with FOL-005

Follicum AB receives Notice of Allowance from the U.S. Patent Office for method of stimulating hair growth with FOL-005

Report this content

Follicum AB ("Follicum") announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 16/176,201 which when granted confers expanded protection for Follicum's product candidate FOL-005.

Follicum has already two granted US patents in this patent family (US 9,381,149 and US 10,137,169), conferring protection for different forms of FOL-005. Follicum has subsequently submitted a follow-up application, called Continuing Patent Application, which extends the protection around the therapeutic use of FOL-005 for which Follicum now has received a Notice of Allowance. Notice of Allowance means that the US patent office, intends to grant the company's patent application after any administrative action by both parties has been implemented. When the patent is granted it can be kept in force until 2032.

CEO Jan Alenfall comments
- We are very pleased to receive this Notice of Allowance which is an important step in our global patent strategy. It provides additional commercialization opportunities in the United States which is one of the largest markets for Follicum, and an extended product protection for our drug candidate is thus extremely important.

About FOL-005
FOL-005 is a modified, short version of the endogenous protein, osteopontin. In two completed clinical studies, treatment withFOL-005 has been shown to be effective and safe. The first study was done in healthy volunteers while the other one was conducted in alopecia patients, i.e. in men with incipient baldness. In both studies, patients were treated at the clinic with intradermal injections, 2 or 3 times a week. Planning for a phase II study is currently underway aiming at investigating the hair-stimulating effect of treatment with different doses of the new topical formulation.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB

Telephone: +46 46 19 21 97
Email: info@follicum.com

This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 17 September 2019.

About Follicum AB
Follicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com


Documents & Links